Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Jiří, Minařík"'
Autor:
Martin Čerňan, Tomáš Szotkowski, Jiří Minařík, Milan Kolář, Pavel Sauer, Vojtěch Látal, Jana Zapletalová, Tomáš Papajík
Publikováno v:
Life, Vol 12, Iss 8, p 1184 (2022)
Vaccination is an important tool in the fight against the COVID-19 pandemic in patients with haematologic malignancies. The paper provides an analysis of the course of breakthrough SARS-CoV-2 infection in a group of vaccinated patients with haematolo
Externí odkaz:
https://doaj.org/article/71374c0f800f4aacabaf1150c0777feb
Autor:
Lucie Broskevicova, Kateřina Growková, Jana Filipova, Jiří Minařík, Roman Hájek, Ludek Pour, Giovanni Stracquadanio, Lucie Rihova, Fedor Kryukov, Juli R. Bagó, Lubica Harvanova, Zuzana Chyra, Lucie Cerna, Michal Simicek, Vladimir Maisnar, Martina Zatopkova, Renata Bezdekova, Matous Hrdinka, David Žihala, Alexandra Jungova, Viola Fanfani, Tereza Sevcikova, Jana Smejkalová, Tereza Popkova, Anjana Anilkumar Sithara, Tomas Jelinek
Publikováno v:
Zátopková, M, Ševčíková, T, Fanfani, V, Chyra, Z, Rihova, L, Bezdekova, R, Žihala, D, Growková, K, Filipova, J, Černá, L, Broskevičová, L, Kryukov, F, Minařík, J, Smejkalová, J, Maisnar, V, Harvanová, L, Pour, L, Jungova, A, Popková, T, Bago, J R, Anilkumar Sithara, A, Hrdinka, M, Jelinek, T, Šimíček, M, Stracquadanio, G & Hajek, R 2021, ' Mutation landscape of multiple myeloma measurable residual disease : identification of targets for precision medicine ', Blood Advances . https://doi.org/10.1182/bloodadvances.2020003876
Blood Advances
Blood Advances
Multiple myeloma (MM) measurable residual disease (MRD) persisting after treatment is an adverse prognostic factor for progression free survival (PFS) and overall survival.1Genomic mutations occurred in the remaining clonal aberrant plasma cells (A-P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::416410420e5d98efe4fb72c3bcc142a6
https://doi.org/10.1182/bloodadvances.2020003876
https://doi.org/10.1182/bloodadvances.2020003876
Autor:
Jiří Minařík
Publikováno v:
Klinická farmakologie a farmacie. 35:70-77
Lecba mnohocetneho myelomu (MM) se v poslednich letech vyviji znacným tempem. Za hlavni milniky, ktere vedly k zasadnimu zlepseni prognozy, jsou považovany: posunuti lecby do casnějsi (bezpřiznakove) faze onemocněni, důraz na dosaženi negativi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::838b45412c318d350f37d49bf07c75e3
https://doi.org/10.36290/far.2021.020
https://doi.org/10.36290/far.2021.020
Autor:
Michal Sýkora, Lukas Stejskal, Alexandra Jungova, Vladimir Maisnar, Petr Kessler, Viera Sandecká, Jana Ullrychova, Adriana Heindorfer, Luděk Pour, Tomas Pika, Jan Straub, Martin Stork, Jiří Minařík, Lucie Brožová, Roman Hájek, Ivan Spicka, Tomas Jelinek, Petr Pavlicek, David Starostka, Sabina Ševčíková, Jakub Radocha, Marek Wrobel
Publikováno v:
European Journal of Haematology. 107:466-474
Objectives This study compared the use of bortezomib in different combination regimens in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible. Patients and methods We analyzed data from the Registry of Monoclonal Gammopath
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e1c1a0103ebd62cfdd0ad071e031465
https://doi.org/10.1111/ejh.13683
https://doi.org/10.1111/ejh.13683
Autor:
Petra Hübnerová, Marta Karhanová, Petra Krhovská, Jiří Minařík, Petr Mlčák, Barbora Pašková, Zuzana Schreiberová, Irena Šínová, Jana Zapletalová, Martin Šín
Publikováno v:
Acta Ophthalmologica. 101
The aim of this pilot study was to assess oxygen saturation in retinal blood vessels in patients with monoclonal gammopathies (MGs).Thirty-one patients with MGs (11 women and 20 men, mean age 65.9 ± 8.9 years) were enrolled during 2016-2020. The pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fe71962db4218f6481fc494909c4383
https://doi.org/10.1111/aos.15239
https://doi.org/10.1111/aos.15239
Autor:
Viera SANDECKA, Luděk POUR, Ivan ŠPIČKA, Jiří MINAŘÍK, Jakub RADOCHA, Tomáš JELÍNEK, Petr PAVLÍČEK, Alexandra JUNGOVÁ, Petr KESSLER, Marek WRÓBEL, Martin ŠTORK, Jan ŠTRAUB, Tomáš PIKA, Lenka ČÁPKOVÁ, Sabina ŠEVČÍKOVÁ, Vladimír MAISNAR, Roman HÁJEK
Publikováno v:
Neoplasma. 69(6)
We assessed the outcomes of pomalidomide and dexamethasone treatment in relapsed/refractory multiple myeloma (RRMM) patients with ≥1 prior line of therapy. We analyzed the data of all RRMM patients treated with pomalidomide and dexamethasone at nin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0549b45be2adbb252d16072e7e0e3d59
https://pubmed.ncbi.nlm.nih.gov/36591805
https://pubmed.ncbi.nlm.nih.gov/36591805
Autor:
Monika Vlachová, Jana Gregorová, Petra Vychytilová-Faltejsková, Natalia Anna Gabło, Lenka Radová, Lenka Pospíšilová, Martina Almáši, Martin Štork, Zdeňka Knechtová, Jiří Minařík, Tereza Popková, Tomáš Jelínek, Roman Hájek, Luděk Pour, Lucie Říhová, Sabina Ševčíková
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences; Volume 23; Issue 23; Pages: 14765
International Journal of Molecular Sciences; Volume 23; Issue 23; Pages: 14765
Extramedullary multiple myeloma (EMD) is an aggressive disease; malignant plasma cells lose their dependence in the bone marrow microenvironment and migrate into tissues. EMD is a negative prognostic factor of survival. Using flow cytometry and next-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d5e9a754ed836a91b7d0954c858bebd
https://is.muni.cz/publication/2235241
https://is.muni.cz/publication/2235241
Autor:
Jiří Minařík, Sabina Ševčíková
Publikováno v:
Cancers. 14:5759
The treatment of multiple myeloma (MM) has undergone a significant paradigm shift in the last 20 years, from conventional chemotherapy to more tumor-specific treatments, based on the interference with pathogenesis of the malignant clone as well as th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f053b3953bd1ac75cfce7156f26b498
https://doi.org/10.3390/cancers14235759
https://doi.org/10.3390/cancers14235759
Autor:
Jeffrey A. Zonder, Alexandra Jungova, Magda Bařinová, Katja Weisel, Roman Hájek, Evangelos Terpos, Frits van Rhee, Rafat Abonour, Jorge Vela-Ojeda, Michael A. Thompson, Robert M. Rifkin, Jin Lu, Jennifer Elliott, Xavier Leleu, Vladimir Maisnar, Kenny Galvez, Ajai Chari, Faith E. Davies, Lenka Capkova, Jiří Minařík, Caitlin Costello, Lucie Brozova, Jan Straub, Jesus G. Berdeja, Noemi Puig, Hans C. Lee, Kaili Ren, Mario Boccadoro, Jiří Šilar, Saad Z. Usmani, Dawn Marie Stull, Gordon Cook, Matyáš Kuhn, Luděk Pour, Andrew Spencer, Vania Tm Hungria
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Aim]: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbb2eb25f28b45fad8a319815d33ed8e
http://hdl.handle.net/10261/261619
http://hdl.handle.net/10261/261619
Autor:
Alexandra Jungova, Luděk Pour, Tomas Jelinek, Jakub Radocha, M Sýkora, Evžen Gregora, A. Heindorfer, Lucie Brožová, Roman Hájek, Vladimir Maisnar, Ivan Spicka, Jiří Minařík
Publikováno v:
Annals of Hematology. 98:951-962
The main goal was to find a simple prognostic to evaluate overall survival of patients older than 65 years of age with myeloma. Retrospective registry-based analysis from the Registry of Monoclonal Gammopathies was conducted. Patients over 65 years w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43fb65f39771fb8db852a2ecc020b243
https://doi.org/10.1007/s00277-018-3568-2
https://doi.org/10.1007/s00277-018-3568-2